In the WU-KONG 6 pivotal study, sunvozertinib demonstrated a confirmed ORR of 60.8% in Chinese patients with NSCLC with EGFR exon 20 insertion mutations [52]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.